Polymorphisms of pharmacogenetic candidate genes affect etomidate anesthesia susceptibility

Lulin Ma1, Yan Huang1,2†, Shiqian Huang1, Feng Xu1, Yafeng Wang1, Shuai Zhao3, Daling Deng1, Yuanyuan Ding1, Tianhao Zhang1, Wenjing Zhao1 and Xiangdong Chen1*

1Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Anesthesiology, The First People’s Hospital of Jiangxia District, Wuhan, China, 3Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, China

Purpose: Etomidate is widely used in general anesthesia and sedation, and significant individual differences are observed during anesthesia induction. This study aimed to explore the molecular mechanisms of different etomidate susceptibility at the genetic level.

Methods: 128 patients were enrolled in the study. The bispectral index (BIS), mean arterial pressure (MAP) and heart rate (HR) were recorded when the patients entered the operating room for 5 min, before the administration of etomidate, 30 s, 60 s, 90 s, 120 s and 150 s after the administration of etomidate, and the corresponding single nucleotide polymorphisms (SNPs) were analyzed.

Results: Significant individual differences were observed in etomidate anesthesia. The results of two-way ANOVA showed that CYP2C9 rs1559, GABRB2 rs2561, GABRA2 rs279858, GABRA2 rs279863 were associated with the BIS value during etomidate anesthesia; UGT1A9 rs11692021 was associated with the Extended Observer’s Assessment of Alertness and Sedation (EOAA/S) score during etomidate anesthesia; GABRB2 rs2561 was associated with MAP. Multiple linear stepwise regression model results showed that CYP2C9 rs1559, GABRA2 rs279858 and GABRB2 rs2561 were associated with the BIS value and UGT1A9 rs11692021 was associated with the EOAA/S score; GABRB2 rs2561 was associated with MAP.

Conclusion: GABRA2 rs279858, GABRB2 rs2561, CYP2C9 rs1559 and UGT1A9 rs11692021 are the SNPs with individual differences during etomidate anesthesia. This is the first to study the SNPs of etomidate, which can provide certain evidence for the future use of etomidate anesthesia and theoretical basis for precision anesthesia.

KEYWORDS
single nucleotide polymorphisms, etomidate, susceptibility, GABRA2, GABRB2, CYP2C9, UGT1A9
Introduction

Etomidate is widely used in general anesthesia and sedation, especially in patients with cardiovascular disease, because it does not inhibit sympathetic tone or myocardial function (Morgan et al., 1975) and has minimal changes in blood pressure and heart rate in patients at typical anesthesia induction doses (Scorgie, 1983). Animal experiments have shown that etomidate is associated with minimal hemodynamic changes or respiratory depression (Forman, 2011). In addition, clinical studies have also shown that etomidate has little effect on cardiovascular disease in patient (Wagner et al., 2014; Chung et al., 2020). However, intravenous etomidate also has corresponding side effects. Involuntary muscle movements often occur with large doses of etomidate (Doenici et al., 1999; Nyman et al., 2011). Adrenal cortical function can be suppressed by previous or high-dose etomidate use (Ge et al., 2013). Some studies have found that adrenal function can be suppressed after a single bolus injection and can last for 48 h in critically ill patients, but whether it has clinical significance is still controversial (den Brinker et al., 2008; Tekwani et al., 2010). Given the advantages and side effects of etomidate, precise dosing is particularly important to ensure the safety and efficacy of anesthesia, which is a key indicator for assessing the quality of anesthesia (Haller et al., 2009).

It is found that different patients have different sensitivity to etomidate. Keita et al. found that factors such as age could change the sensitivity of patients to etomidate (Keita et al., 1998). However, studies at the genetic level have not yet been reported in the literature. Genetic variability represents a fundamental source of interindividual variability in drug dosage (Amstutz and Carleton, 2011), with single nucleotide polymorphisms (SNPs) being critical in determining patient’s response to drugs (Roden et al., 2019). A previous study of our group found that differences at the genetic level could significantly affect the sensitivity of patients to propofol (Zhong et al., 2017). We therefore hypothesized that the diversity of SNPs could affect the susceptibility of different patients to etomidate.

Gamma-aminobutyric acid type A (GABAA) receptors have been confirmed to be the target of etomidate (Franks, 2006). Etomidate mainly acts on the α and β subunits of GABAA (Forman, 2011). Besides, Etomidate inhibits the adrenal cortical axis by inhibiting the enzyme 11β-hydroxylase and mainly is metabolized by hepatic esterase (Valk and Struys, 2021). Etomidate metabolism in animals and humans depends on hepatic esterase activity, which hydrolyzes it to a carboxylic acid and an ethanol leaving group (Forman, 2011). Activation of α2-adrenergic receptors mediates the cardiovascular effects (Paris et al., 2003) and sedative effects of etomidate (Paris et al., 2007). Paris et al. found that etomidate acted as an agonist of α2 adrenergic receptors and its effect on blood pressure was mainly manifested in the increase of blood pressure in vivo mediated by α2B receptors (Paris et al., 2003); They also demonstrated that etomidate could interact with α2-adrenoceptors and lack of α2-adrenoceptor activity might play an important role in mediating etomidate anesthesia in mice (Paris et al., 2007). In addition, the mechanisms of etomidate itself still needs to be studied (Restrepo et al., 2009), but it is similar to propofol. Therefore the mechanisms of propofol is also considered. Combining the above action targets and metabolic mechanisms of etomidate and propofol with the related data in the national library of medicine (NIH), possible SNPs were screened out and corresponding studies were carried out to explore the effect of gene level on etomidate sensitivity.

Materials and methods

Patient recruitment

This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Ethics Approval Number: 2019-S1205). All patients signed informed consent. A total of 128 participants undergoing elective ear nose and throat (ENT) surgery with general anesthesia were recruited from December 2019 to November 2020 at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. All participants denied blood ties. The inclusion criteria were as follows: 1) patients undergoing elective ENT with general anesthesia; 2) age between 20-55 years old; 3) no history of surgery; 4) no history of drug use and addiction, such as opioids, opium, heroin, marijuana, Meth, ecstasy and K powder, etc; 5) no hypertension, coronary heart disease, diabetes and other medical history; 6) ASA I or II. Exclusion criteria: 1) History of allergy or drug dependence; 2) Pregnancy or breastfeeding; 3) Abnormal liver and kidney function; 4) History of hypertension, diabetes, coronary heart disease and other cardiovascular diseases; 5) Patients with any neurological or psychological disease; 6) Other diseases that may affect the test results, for example, patients with adrenal insufficiency. The preoperative visits were all conducted by the same anesthesiologist.

Anaesthesia procedure and monitoring

The patients were not given premedication before surgery. After the patients entered the operating room, the non-invasive blood pressure, electrocardiogram, bispectral index (BIS) and blood oxygen saturation of the patient were routinely monitored,
and the Extended Observer’s Assessment of Alertness and Sedation (EOAA/S), mean arterial pressure (MAP), heart rate (HR) and BIS values were recorded for 5 min after the patient entered the room (T1), before the administration of etomidate (T2), 30 s (T3), 60 s (T4), 90 s (T5), 120 s (T6) and 150 s (T7) after the etomidate administration. The regular dose of etomidate takes 15–20 s to take effect, the effect reaches its peak in about 1 min, and the duration of action is about 2–3 min (van den Heuvel et al., 2013). In addition, in clinical experiments, it was observed that the BIS value of some patients had increased at 180s after the administration of etomidate. Therefore, the cut-off time of this experimental study was 150s after the etomidate administration. Etomidate was injected intravenously at 0.1 mg/kg in about 15 s. During the entire observation process, only etomidate was given, excluding the influence of other drugs. The EOAA/S score criteria were presented in Table 1 (Kim et al., 2015).

### DNA sample collection and DNA extraction

Four milliliter venous blood was collected from each patient 10 min prior to induction of anesthesia. Samples were stored at -80°C and subsequently extracted using the TIANamp Genomic DNA kit. The Snap shot technology system was used to determine genotypes based on detection by MALDI-TOF MS (Sequenom Inc., San Diego, CA, United States).

### Statistical analysis

All statistical analyses were performed by SPSS 27.0 software (IBM, United States). Categorical variables were described with percentages, and continuous variables were presented with mean ± standard deviation (SD). Patients were divided into two groups, homozygous for the major allele, heterozygous for the major allele and homozygous for the minor allele (Zhong et al., 2017; Zhu et al., 2022). Differences between the two groups at different time points were calculated using a two-way ANOVA test, followed by Sidak’s multiple comparisons tests. The chi-square test was used to investigate the Hardy-Weinberg equilibrium (HWE) for each SNP, and $p < 0.05$ was considered as deviation from equilibrium. To further evaluate the independent influence of these clinical factors (age, genotype, gender, and BMI), multiple stepwise linear regression analysis was applied, with $p < 0.05$ indicating statistical significance. Two-tailed $p < 0.05$ was used in the statistical analysis.

### Results

#### Characteristics of participants

Ultimately, 128 patients were enrolled in the study. 26 patients were excluded due to the following reasons: 1) blood samples or clinical data were not completely recorded ($n = 20$); 2) severe muscle fibrillation led to trial termination ($n = 1$); 3) HR was too fast after etomidate administration ($n = 1$); 4) propofol was added to patients who developed irritability after etomidate administration ($n = 2$); 5) endotracheal intubation was performed immediately after the upper airway was obstructed ($n = 1$); 6) HR was less than 50 bpm after the etomidate administration, then atropine was given to increase the HR ($n = 1$). Finally, a total of 102 patients (male/female, 57/45) were collected and genotyped. The age (years) and BMI (kg/m²) of the participants were 37.60 ± 8.62 and 23.88 ± 3.30 respectively. The experimental flow chart was shown in Figure 1.

### Significant individual differences in bispectral index and EOAA/S scores after etomidate anesthesia

Significant individual differences were observed in etomidate induced anesthesia. Besides, there was a time-dependent decrease in BIS and EOAA/S scores. The average

| Score | Description | Level of sedation or anaesthesia |
|-------|-------------|----------------------------------|
| 5     | Responds readily to name spoken | Minimal                        |
| 4     | Lethargic response to name spoken | Moderate                      |
| 3     | Responds after name called loudly/repeatedly | Moderate                   |
| 2     | Purposeful response to mild-to-moderate shaking | Moderate                   |
| 1     | Responds to trapezius squeeze | Deep                           |
| 0T    | No response to trapezius squeeze | Light general anaesthesia     |
| 0E    | No response to electrical stimulation | Deeper general anaesthesia    |
BIS values of patients after entering the operating room for 5 min and before etomidate administration were 92.84 ± 5.289 and 92.24 ± 5.421 respectively. All patients had an EOAA/S score of 5 at the both time points. 30 s after the etomidate, the maximum BIS of the patients was 99, and the minimum was 60. The difference between the two was 1.65 times, and the difference between EOAA/S scores was 2.5 times; The maximum value of the BIS at the 60s was 99, and the minimum was 30. The difference between the two was 3.3 times. The EOAA/S score was scattered as the highest score and the lowest score, and the difference between the two was 5 points; At 90 s, the maximum value of the BIS was 99, and the minimum was 29. The difference between the two was 3.4 times. The difference in the EOAA/S score was 5 points; At 150 s, the maximum BIS of the patients was 98, and the minimum was 28. The difference between the two was 3.2 times. The EOAA/S score differed by 5 points (Figure 2).

### Individual differences in hemodynamics after etomidate anesthesia

There were individual differences in hemodynamics during etomidate anesthesia. However, etomidate has little effect on the hemodynamics of patients. The HR was 75.06 ± 14.39 bpm when the patients were quiet for 5 min after entering the operating room, and the HR before etomidate was 75.87 ± 13.72 bpm. The HR at 30 s, 60 s, 90 s, 120s and 150s were 76.36 ± 14.33 bpm, 78.26 ± 13.75 bpm, 78.67 ± 12.75 bpm, 76.72 ± 12.57 bpm and 75.98 ± 12.84 bpm, respectively; Compared with the basal HR, the HR change rate at 30s, 60s, 90s, 120s and 150s after etomidate anesthesia were 0.6% ± 4.4%, 3.5% ± 8.1% ($p < 0.0001$), 4.7% ± 13.4% ($p = 0.0005$), 2.1% ± 12.9% and 0.9% ± 11%, respectively; MAP was 91.84 ± 11.28 mmHg when the patients were quiet for 5 min after entering the operating room, and MAP was 75.87 ± 13.72 mmHg before etomidate anesthesia. MAP at 30 s, 60 s, 90 s, 120s and 150s were 92.25 ± 11.40 mmHg, 91.70 ± 11.88 mmHg, 91.03 ± 11.65 mmHg, 91.96 ± 11.88 mmHg, and 92.80 ± 11.74 mmHg, respectively. Compared with the basal MAP, the MAP change rate at 30 s, 60 s, 90 s, 120 s, and 150 s were 0.5% ± 2.9%, -0.1% ± 5.0%, -0.8% ± 5.9%, 0.3% ± 7.2% and 1.2% ± 7.1%, respectively (Figure 3).

### Genotyping results

A total of 48 SNPs were detected in 102 patients. No genetic variants were found in GABRA2 rs2555, CYP11B1 rs1584, CES1 rs1066 and CYP2C19 rs1557 in all subjects, and all patients were homozygous for the major allele. GR1N2B rs3764028, ABCB1 rs1045642, BCHE
FIGURE 2
Individual differences in BIS and EOAA/S scores during etomidate anesthesia. (A) BIS and EOAA/S scores when the patients were quiet for 5 min after entering the operating room; (B) BIS and EOAA/S scores before etomidate administration; (C), (D), (E), (F), and (G) BIS value and EOAA/S score at 30 s, 60 s, 90 s, 120 s and 150 s. T1, 5 min after the patients entered the room; T2, before the administration of etomidate; T3, 30 s; T4, 60 s; T5, 90 s; T6, 120 s; T7, 150 s after the etomidate.
rs590 and CACNA1A rs773 did not conform to Hardy–Weinberg equilibrium (HWE). The remaining 40 SNPs had genetic variation in patients and were in compliance with the HWE equilibrium (Table 2).

**Correlation between single nucleotide polymorphisms genotyping and etomidate-induced sedation depth sensitivity**

The sedation depth induced by etomidate was assessed using the BIS and EOAA/S scores. According to the SNP genotyping results, the patients were divided into two groups: 1) homozygous for major allele; 2) heterozygote for major allele and homozygous for minor allele. For BIS, 4 SNPs (CYP2C9 rs1559, GABRB2 rs2561, GABRA2 rs279858, GABRA2 rs279863) showed significant differences at different time points; for EOAA/S score, only one SNP (UGT1A9 rs11692021) had a statistically significant difference (Figure 4).

**Multiple linear regression analysis of the relationship between multiple factors and bispectral index as well as EOAA/S score**

In order to study the effects of multiple factors (gender, age, BMI) and corresponding SNPs on BIS, a multiple linear stepwise regression model was used to perform regression analysis on these factors. The results showed that CYP2C9 rs1559 and GABRA2 rs279858 had statistical significance at T5 (120 s) after intravenous etomidate; GABRB2 rs2561 had statistical significance at T6 (120 s); GABRB2 rs2561 had statistical significance at T7 (150 s). However, there was no significant difference in age, gender and BMI at any time pointe (Table 3).

In order to study the effects of multiple factors (gender, age, BMI) and the corresponding SNPs on EOAA/S scores, a multiple
A linear stepwise regression model was used to perform regression analysis on these factors. The results showed that gender differences were statistically significant at T3 (30 s); The UGT1A9 rs11692021 was statistically significant at T4 (60 s); Gender and BMI were statistically significant at T5 (90 s); BMI was statistically significant at T6 (120 s) and T7 (150 s) (Table 4).

**Correlation between single nucleotide polymorphisms genotyping and hemodynamics**

MAP was used as one of the hemodynamic indexes. According to the SNP genotyping results, the patients were divided into two groups: 1) homozygous for major allele; 2) heterozygote for major allele and homozygous for minor allele. Only one SNP (GABRB2 rs2561) was significantly different in MAP (Figure 5).

**Multiple linear regression analysis of the relationship between multiple factors and MAP**

In order to study the effects of multiple factors (gender, age, BMI) and the corresponding SNPs on MAP, a multiple linear stepwise regression model was used to perform regression analysis on these factors. The results showed that age and GABRB2 rs2561 were statistically significant at T3 (30s), T4 (60s) and T5 (90s); Age, GABRB2 rs2561 and BMI were statistically significant at T6 (120s) and T7 (150s) (Table 5).

**Discussion**

In the present study, we found that there were obvious individual differences during the etomidate anesthesia. According to the target of etomidate and its metabolic mechanisms, 48 possible SNPs were screened in this experiment. Among them, CYP2C9 rs1559, GABRA2 rs279858 and GABRB2 rs2561 were associated with BIS values during etomidate anesthesia; UGT1A9 rs11692021 was associated with MOAA/S score; In addition, GABRB2 rs2561 were associated with MAP.

**GABRA2 rs279858 and GABRB2 rs2561 were related to depth of sedation and hemodynamics**

Previous studies have confirmed that etomidate mainly acts on GABAA receptors (Franks, 2006; Weir et al., 2017). A type of
GABAAR closely related to anesthetics involves a combination of two alpha, two beta and gamma (α1β2γ2) (Nutt, 2006). The α and β subunit are the main acting subunit of etomidate (Forman, 2011). However several studies have found that the hypnotic effects of etomidate involve GABAARs containing β2 and β3 (Hill-Venning et al., 1997; Weir et al., 2017). GABAARs containing β1 are much less sensitive to the effects of etomidate. The affinity of etomidate is also enhanced by the presence of the γ subunit, while the α subtype has a weaker affinity (Brohan and Goudra, 2017). Therefore, the GABRB2 and GABRA2, as the main targets of etomidate, play an important role in etomidate anesthesia.

**TABLE 3** Multiple linear regression analysis of clinical variables related to BIS.

| Independent variable | Unstandardized coefficients | SE  | Standardized coefficients | t    | p    |
|----------------------|-----------------------------|-----|---------------------------|------|------|
| T5                   |                             |     |                           |      |      |
| CYP2C9 rs1559        | 9.097                       | 3.85| 0.224                     | 2.363| 0.02 |
| GABRA2 rs279858      | −11.755                     | 4.482| −0.249                    | −2.622| 0.01 |
| Model fit: R = 0.328, R2 = 0.108, adjust R2 = 0.09, DW = 1.839, F = 5.984, p = 0.004 |
| T6                   |                             |     |                           |      |      |
| GABRB2 rs2561        | 8.288                       | 4.034| 0.201                     | 2.054| 0.043|
| Model fit: R = 0.201, R2 = 0.04, adjust R2 = 0.031, DW = 1.867, F = 4.221, p = 0.043 |
| T7                   |                             |     |                           |      |      |
| GABRB2 rs2561        | 9.048                       | 4.02 | 0.22                      | 2.251| 0.027|
| Model fit: R = 0.22, R2 = 0.048, adjust R2 = 0.039, DW = 1.777, F = 5.065, p = 0.027 |
| Min BIS              |                             |     |                           |      |      |
| GABRB2 rs2561        | 9.470                       | 3.959| 0.233                     | 2.392| 0.019|
| Model fit: R = 0.233, R2 = 0.054, adjust R2 = 0.045, DW = 1.755, F = 5.723, p = 0.019 |

DW: Durbin–Watson test. SE: standard error. BMI: body mass index. Min: minimum. T1, 5 min after the patients entered the room; T2, before the administration of etomidate; T3, 30 s; T4, 60 s; T5, 90 s; T6, 120 s; T7, 150 s after the etomidate.
### TABLE 4 Multiple linear regression analysis of clinical variables related to EOAA/S score.

| Independent variable | Unstandardized coefficients | SE | Standardized coefficients | t  | p    |
|----------------------|-----------------------------|----|---------------------------|----|------|
| T3                   |                             |    |                           |    |      |
| Gender               | 0.545                       | 0.151 | 0.340                     | 3.619 | <0.001 |
| Model fit: R = 0.340, R^2 = 0.116, adjust R^2 = 0.107, DW = 2.011, F = 13.095, p < 0.001 |
| T4                   |                             |    |                           |    |      |
| UGT1A9 rs11692021     | 0.717                       | 0.252 | 0.274                     | 2.845 | 0.005 |
| Model fit: R = 0.274, R^2 = 0.075, adjust R^2 = 0.066, DW = 2.161, F = 8.096, p = 0.005 |
| T5                   |                             |    |                           |    |      |
| BMI                  | -0.109                      | 0.043 | -0.247                    | -2.512 | 0.014 |
| Gender               | 0.629                       | 0.285 | 0.217                     | 2.205 | 0.030 |
| Model fit: R = 0.292, R^2 = 0.085, adjust R^2 = 0.067, DW = 1.993, F = 4.619, p = 0.012 |
| T6                   |                             |    |                           |    |      |
| BMI                  | -0.114                      | 0.045 | -0.245                    | -2.524 | 0.013 |
| Model fit: R = 0.245, R^2 = 0.060, adjust R^2 = 0.050, DW = 2.082, F = 6.369, p = 0.013 |
| T7                   |                             |    |                           |    |      |
| BMI                  | -0.147                      | 0.045 | -0.314                    | -3.030 | 0.001 |
| Model fit: R = 0.314, R^2 = 0.098, adjust R^2 = 0.089, DW = 1.835, F = 10.913, p = 0.001 |

DW: Durbin–Watson test. SE: standard error. BMI: body mass index. T1, 5 min after the patients entered the room; T2, before the administration of etomidate; T3, 30 s; T4, 60 s; T5, 90 s; T6, 120 s; T7, 150 s after the etomidate.

### TABLE 5 Multiple linear regression analysis of clinical variables related to MAP.

| Independent variable | Unstandardized coefficients | SE | Standardized coefficients | t  | p    |
|----------------------|-----------------------------|----|---------------------------|----|------|
| T3                   |                             |    |                           |    |      |
| Age                  | 0.601                       | 0.116 | 0.454                     | 5.193 | <0.001 |
| GABBR2 rs2561        | -5.007                      | 2.376 | -0.184                    | -2.107 | 0.038 |
| Model fit: R = 0.492, R^2 = 0.242, adjust R^2 = 0.227, DW = 2.000, F = 15.801, p < 0.001 |
| T4                   |                             |    |                           |    |      |
| Age                  | 0.489                       | 0.125 | 0.355                     | 3.919 | <0.001 |
| GABBR2 rs2561        | -6.871                      | 2.564 | -0.243                    | -2.680 | 0.009 |
| Model fit: R = 0.432, R^2 = 0.187, adjust R^2 = 0.170, DW = 2.030, F = 11.365, p < 0.001 |
| T5                   |                             |    |                           |    |      |
| Age                  | 0.477                       | 0.122 | 0.353                     | 3.907 | <0.001 |
| rs2561               | -7.173                      | 2.506 | -0.258                    | -2.863 | 0.005 |
| Model fit: R = 0.439, R^2 = 0.193, adjust R^2 = 0.177, DW = 2.177, F = 11.828, p < 0.001 |
| T6                   |                             |    |                           |    |      |
| Age                  | 0.560                       | 0.117 | 0.406                     | 4.781 | <0.001 |
| GABBR2 rs2561        | -7.482                      | 2.421 | -0.265                    | -3.090 | 0.003 |
| BMI                  | 0.669                       | 0.308 | 0.186                     | 2.168 | 0.033 |
| Model fit: R = 0.543, R^2 = 0.295, adjust R^2 = 0.274, DW = 2.024, F = 13.69, p < 0.001 |
| T7                   |                             |    |                           |    |      |
| Age                  | 0.568                       | 0.116 | 0.417                     | 4.899 | <0.001 |
| GABBR2 rs2561        | -6.540                      | 2.398 | -0.234                    | -2.727 | 0.008 |
| BMI                  | 0.688                       | 0.306 | 0.194                     | 2.250 | 0.027 |
| Model fit: R = 0.540, R^2 = 0.292, adjust R^2 = 0.270, DW = 1.881, F = 13.447, p < 0.001 |

DW: Durbin–Watson test. SE: standard error. BMI: body mass index. T1, 5 min after the patients entered the room; T2, before the administration of etomidate; T3, 30 s; T4, 60 s; T5, 90 s; T6, 120 s; T7, 150 s after the etomidate.
To date, there is no literature on the correlation between etomidate sensitivity and SNPs. However, some studies have reported the relationship between propofol and SNPs, while propofol and etomidate have similar mechanisms of action. Zeng et al. found that GABRB2 rs3816596 and GABRA1 rs4263535 polymorphisms were associated with susceptibility to propofol sedation. ABRA1 rs1157122 and GABRB2 rs76774144 polymorphisms were associated with the degree of blood pressure drop after propofol infusion (Zeng et al., 2022). A previous study by our group found an association between GABAA1 receptor SNP rs2279020 and sensitivity to BIS. In addition, dominant mutations in GABAA1 rs2279020 and GABAA2 rs11503014 were putatively associated with cardiovascular susceptibility to propofol anesthesia (Zhong et al., 2017). Our experimental study found that GABRB2 rs2561 was associated with the BIS value after etomidate sedation. Compared with the major gene homozygous group, the major gene heterozygous group and the minor gene homozygous group showed higher BIS values under the same conditions, but compared with the major gene homozygous group, the major gene heterozygous group and the minor gene homozygous group showed lower MAP values. Furthermore, we also found that GABRA2 rs279858 was associated with the BIS value after etomidate sedation. Compared with the major gene homozygous group, the major gene heterozygous group and the minor gene homozygous group showed lower BIS values under the same conditions. Therefore, we conclude that the GABRB2 rs2561 is related to the BIS and MAP of etomidate-induced anesthesia; GABRA2 rs279858 is related to the BIS induced by etomidate.

CYP2C9 rs1559 and UGT1A9 rs11692021 were related to depth of anesthesia

CYP2C9 and UGT1A9 are the major metabolic genes for many drugs, including anesthetics. Propofol is primarily metabolized by CYP2B6 and CYP2C enzymes. The enzymes SULT1A1 and NQO1 are involved in the later steps of propofol metabolism (Restrepo et al., 2009). A previous study found that UGT1A9 genotype was an independent predictor of propofol concentrations immediately and 10 min after the end of continuous infusion in children. Propofol distribution constant was higher in carriers of the polymorphic UGT1A9 C allele. Carriers of the polymorphic CYP2B6 T allele received significantly lower total and initial doses of propofol (Pavlovic et al., 2020). CYP2C9 (c.1075A>C, rs1057910) was associated with BIS, target-controlled infusion (TCI)/effector concentration of propofol and TCI/plasma concentration of propofol values (Tong et al., 2021); CYP2C9*2 patients required higher propofol concentrations to achieve loss of consciousness (LOC) (Khan et al., 2014). Khan et al. found that patients with the UGT1A9-331C/T gene had higher propofol clearance than those without and required higher induction doses. UGT1A9-1818T/C patients took longer to reach the LOC (Khan et al., 2014). In addition, compared with patients carried UGT1A9 -440C/T CT and TT, those carried UGT1A9 -440C/T CC showed shorter durations of Observer’s Assessment of Alertness/Sedation (OAA/S) by up to 4 points, shorter BIS times to reach 80, and higher corresponding effect-site concentrations (Wang et al., 2017). Our results suggest that CYP2C9 rs1559 and UGT1A9 rs11692021 were closely related to the BIS and MOAA/S score induced with etomidate. Therefore, we can conclude that the metabolic pathway of etomidate is similar to that of propofol. And the genes that affect propofol metabolism also affect etomidate.

Limitations

The sample size of this study is relatively small. We will further expand the sample size in the follow-up study to enhance the statistical power of the relevant SNP to verify the results of this study. Besides, the genes we selected are only based on the currently known polymorphisms, and many genes that have not yet been discovered due to genetic polymorphisms may have an effect on the effect of etomidate. Moreover, in this study, two-way ANOVA and multiple linear regression models were used to jointly verify the differential SNPs. However, results presented were not adjusted for multiple comparisons. When we adjusted for multiple comparisons, these associations were no longer significant.
statistically significant. The reason for this result may be related to the size of the sample. Therefore, we will increase the sample size for further verification in subsequent experiments. However, the current findings still have great inspiration, prompting us to carry out further research.

**Conclusion**

In summary, our study suggested that significant individual differences were observed in etomidate induced anesthesia. GABRA2 rs279858, GABRB2 rs2561, CYP2C9 rs1559 and UGT1A9 rs11692021 are the SNPs with individual differences during etomidate anesthesia. This is the first to study the SNPs of etomidate, which may provide certain evidence for the future use of etomidate anesthesia.

**Data availability statement**

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author.

**Ethics statement**

The studies involving human participants were reviewed and approved by Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. The patients/participants provided their written informed consent to participate in this study.

**References**

Amstutz, U., and Carleton, B. C. (2011). Pharmacogenetic testing: Time for clinical practice guidelines. *Clin. Pharmacol. Ther.* 89 (6), 924–927. doi:10.1038/cpt.2011.18

Brohan, J., and Goudra, B. G. (2017). The role of GABA receptor agonists in anesthesia and sedation. *CNS Drugs* 31 (10), 845–856. doi:10.1007/s40263-017-0463-7

Chung, M., Santer, P., Rauch, D., Zhao, Y., Zhao, T., Strom, J., et al. (2020). Use of etomidate in patients with heart failure undergoing noncardiac surgery. *Br. J. Anaesth.* 125 (6), 943–952. doi:10.1016/j.bja.2020.06.059

den Brinker, M., Hokken-Koelega, A. C., Hazelzet, J. A., de Jong, F. H., Hop, W. C., and Joostens, K. F. (2008). One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis. *Intensive Care Med.* 34 (1), 163–168. doi:10.1007/s00134-007-0836-3

Doenicke, A. W., Rosten, M. F., Kugler, J., Kroll, H., Foss, J., and Ostwald, P. (1999). Reducing myoclonus after etomidate. *Anesthesiology* 90 (1), 113–119. doi:10.1097/00000542-199901000-00017

Forman, S. A. (2011). Clinical and molecular pharmacology of etomidate. *Anesthesiology* 114 (3), 695–707. doi:10.1097/ALN.0b013e3181ff7265

Franko, N. P. (2006). Molecular targets underlying general anesthesia. *Br. J. Pharmacol.* 147 (1), 572–581. doi:10.1038/bjp.0706441

Ge, R., Pina, E., Cotten, J. F., and Raines, D. E. (2013). Adrenocortical suppression and recovery after continuous hypnotic infusion: Etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate. *Crit. Care* 17 (1), R20. doi:10.1186/cc12494

Haller, G., Stoevlinder, J., Myles, P. S., and McNeil, J. (2009). Quality and safety indicators in anesthesia: A systematic review. *Anesthesiology* 110 (5), 1158–1175. doi:10.1097/ALN.0b013e3181a1093b

Hill-Venning, C., Bedell, D., Peters, J. A., and Lambert, J. J. (1997). Subunit-dependent interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor. *Br. J. Pharmacol.* 120 (5), 749–756. doi:10.1038/sj.bjp.0700927

Keita, H., Lasocki, S., Hennzel-Rouelé, D., Desmonts, J. M., and Mantz, J. (1998). Aging decreases the sensitivity of the GABA carrier to propofol and etomidate. *Br. J. Anaesth.* 81 (2), 249–250. doi:10.1093/bja/81.2.249

Khan, M. S., Zetterlund, E. L., Gréen, H., Oscarsson, A., Zackrisson, A. L., Svahnberg, E., et al. (2014). Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment. *Basic Clin. Pharmacol. Toxicol.* 115 (6), 565–570. doi:10.1111/bcpt.12277

Kim, T. K., Nidelewski, P. J., Martin, J. F., Obara, S., and Egan, T. D. (2015). Enhancing a sedation score to include truly noxious stimulation: The extended Observer’s assessment of alerterness and sedation (EOAA/S). *Br. J. Anaesth.* 115 (4), 569–577. doi:10.1093/bja/aev306

Morgan, M., Lumley, J., and Whitwam, J. G. (1975). Etomidate, a new water-soluble non-barbiturate intravenous induction agent. *Lancet* 1 (7913), 955–956. doi:10.1016/s0140-6736(75)90729-5

Nutt, D. (2006). GABAA receptors: Subtypes, regional distribution, and function. *J. Clin. Sleep Med.* 2 (2), S7–S11.

**Author contributions**

This work was primarily conceived by XC and LM, data was collected by YH, and analyzed by LM, SH, FX and YW. Manuscript was written by LM, YH, SH, FX, YW, SZ, DD, YD, TZ, WZ, and XC. Figures were produced by LM. All authors read and approved the final manuscript.

**Funding**

This work was supported by the National Key Research and Development Program of China (grant 2018YFC2001802 to XC); National Natural Science Foundation (grant 82071251 to XC); Hubei Province Key Research and Development Program (grant 2021BCA145 to XC).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Nyman, Y., von Hofsten, K., Ritzmo, C., Eksborg, S., and Lönnqvist, P. A. (2011). Effect of a small priming dose on myoclonic movements after intravenous anaesthesia induction with Etomidate-Lipuro in children. Br. J. Anaesth. 107 (2), 225–228. doi:10.1093/bja/aer129

Paris, A., Hein, L., Brede, M., Brand, P. A., Scholz, J., and Tonner, P. H. (2007). The anesthetic effects of etomidate: Species-specific interaction with alpha 2-adrenoceptors. Anesth. Analg. 105 (6), 1644–1649. doi:10.1213/01.ane.0000286178.96799.cd

Paris, A., Philipp, M., Tonner, P. H., Steindahl, M., Lohse, M., Scholz, J., et al. (2003). Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 99 (4), 889–895. doi:10.1097/00000542-200310000-00022

Pavlovic, D., Budic, I., Jevtovic Stoimenov, T., Stokanovic, D., Marjanovic, V., Stevic, M., et al. (2020). The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on propofol pharmacokinetics in children. Pharmgenomics. Pers. Med. 13, 13–27. doi:10.2147/pgpm.S231329

Restrepo, J. G., Garcia-Martín, E., Martínez, C., and Agúndez, J. A. (2009). Polymorphic drug metabolism in anaesthesia. Curr. Drug Metab. 10 (3), 236–246. doi:10.2174/138920009787846305

Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., et al. (2019). Pharmacogenomics. Lancet 394 (10197), 521–532. doi:10.1016/s0140-6736(19)31276-0

Scorgie, B. (1983). Etomidate infusion. Its use in anaesthesia for general surgery. Anaesthesia 38, 63–65. doi:10.1111/j.1365-2044.1983.tb15182.x

Tekwani, K. L., Watts, H. F., Swier, R. T., Rzechula, K. H., and Kulisad, E. B. (2010). A comparison of the effects of etomidate and midazolam on hospital length of stay in patients with suspected sepsis. A prospective, randomized study. Ann. Emerg. Med. 56 (5), 481–489. doi:10.1016/j.annemergmed.2010.05.034

Tong, Z., Gaudy, A., Tatosian, D., Ramirez-Valle, F., Liu, H., Chen, J., et al. (2021). Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase. Xenobiotica. 51 (12), 1416–1426. doi:10.1080/00498254.2022.2027553

Valk, B. L., and Struys, M. (2021). Etomidate and its analogs: A review of pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 60 (10), 1253–1269. doi:10.1007/s40266-021-01038-6

van den Heuvel, I., Wurm, T. E., Böttiger, B. W., and Bernhard, M. (2013). Pros and cons of etomidate-more discussion than evidence? Curr. Opin. Anaesthesiol. 26 (4), 404–408. doi:10.1097/ACO.0b013e328362a84c

Wagner, C. E., Rick, J. S., Johnson, D., Ahmad, R., Han, X., Ehrenfeld, J. M., et al. (2014). Etomidate use and postoperative outcomes among cardiac surgery patients. Anesthesiology 120 (3), 579–589. doi:10.1097/ALN.0b013e3182a80887

Wang, Y. B., Zhang, R. Z., Huang, S. H., Wang, S. B., and Xie, J. Q. (2017). Relationship between UGT1A9 gene polymorphisms, efficacy, and safety of propofol in induced abortions amongst Chinese population: A population-based study. Biocsi. Rep. 37 (5), BSR20170722. doi:10.1042/bsr20170722

Weir, C. J., Mitchell, S. J., and Lambert, J. J. (2017). Role of GABAA receptor subtypes in the behavioural effects of intravenous general anaesthetics. Br. J. Anaesth. 119 (1), i167–i175. doi:10.1093/bja/aex369

Zeng, Y., Can, S., Chen, M., Fang, C., and Ouyang, W. (2022). GABRA1 and GABBR2 polymorphisms are associated with propofol susceptibility. Pharmacogenomics. Pers. Med. 15, 105–117. doi:10.2147/pgpm.S348170

Zhong, Q., Chen, X., Zhao, Y., Liu, R., and Yao, S. (2017). Association of polymorphisms in pharmacogenetic candidate genes with propofol susceptibility. Sci. Rep. 7 (1), 3343. doi:10.1038/s41598-017-03229-3

Zhu, H., Wang, Y., Wang, Q., Zhao, S., Xu, F., Hu, Z., et al. (2022). Polymorphisms contribute to differences in the effect of rocuronium in Chinese patients. Basic Clin. Pharmacol. Toxicol. 130 (1), 141–150. doi:10.1111/bcpt.13682